Artificial enzymes may help ‘kill’ Covid: Study

PTI

Updated At : 01:14 PM Nov 18, 2022 IST

Unlock Exclusive Insights with The Tribune Premium

Take your experience further with Premium access. Thought-provoking Opinions, Expert Analysis, In-depth Insights and other Member Only Benefits

Yearly Premium ₹999 ₹349/Year

Yearly Premium $49 $24.99/Year

London, November 17

Scientists have developed artificial enzymes programmed to target the genetic code of SARS-CoV-2 and destroy the virus, an advance that may lead to a new generation of antiviral drugs for Covid-19 and its variants.

The study, published in the journal Nature Communications, demonstrated the use of this technology to successfully ‘kill’ live SARS-CoV-2 virus.

Alex Taylor teamed up with Nicholas Matheson to show that these XNAzymes were active against live SARS-CoV-2 virus.

SARS-CoV-2 has the ability to evolve and change its genetic code, leading to new variants against which vaccines are less effective.

To counter this, Taylor not only targeted regions of the viral RNA that mutate less frequently, but also designed three of the XNAzymes to self-assemble into a ‘nanostructure’ that cuts different parts of the virus genome.

The Tribune, now published from Chandigarh, started publication on February 2, 1881, in Lahore (now in Pakistan). It was started by Sardar Dyal Singh Majithia, a public-spirited philanthropist, and is run by a trust comprising five eminent persons as trustees.

The Tribune, the largest selling English daily in North India, publishes news and views without any bias or prejudice of any kind. Restraint and moderation, rather than agitational language and partisanship, are the hallmarks of the newspaper. It is an independent newspaper in the real sense of the term.

The Tribune has two sister publications, Punjabi Tribune (in Punjabi) and Dainik Tribune (in Hindi).

Remembering Sardar Dyal Singh Majithia

Designed and developed by : SORTD

Unlock Exclusive Insights with The Tribune Premium

Suggested Articles